Can somatostatin prevent post-ERCP pancreatitis? Results of a randomized controlled trial
| Autor: | Dimitrios Giannopoulos, Dimitrios Arvanitidis, Roxanne Agaritsi, Panagiotis Kostopoulos, Athanasios Pantes, George Margantinis, Stavros Tsiakos, George H. Sakorafas, George K. Anagnostopoulos |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Male
medicine.medical_specialty Pancreatic disease Placebo Gastroenterology law.invention Bolus (medicine) Randomized controlled trial Double-Blind Method law Internal medicine medicine Humans Aged Cholangiopancreatography Endoscopic Retrograde Hepatology business.industry Middle Aged medicine.disease Somatostatin Pancreatitis Acute pancreatitis Female Complication business |
| Zdroj: | Journal of gastroenterology and hepatology. 19(3) |
| ISSN: | 0815-9319 |
| Popis: | Background: Acute pancreatitis is the most common complication of endoscopic retrogade cholangiopancreatography (ERCP), occurring in 1–10% of patients. Several substances have been used, with negative results, in an attempt to prevent this complication. Methods: We performed a double-blind randomized trial in 372 consecutive patients undergoing diagnostic or therapeutic ERCP to evaluate the role of somatostatin in preventing post-ERCP pancreatitis. The first group received continuous somatostatin infusion for 12 h starting 30 min before ERCP, the second group received a bolus intravenous injection of somatostatin at the time of cannulation of the papilla, and the third group received a placebo. Results: Two patients in each of the somatostatin groups (1.7%) and 12 patients in the placebo group (9.8%) developed pancreatitis (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text